Article by Yippee-Ki-Yay

Veeva Systems Forecast for 2027: How high could the share price go?

Buy signal | Free publication | 23 Apr 2026

🚀 Veeva Systems: The Cloud War Machine Boosting the Pharmaceutical Industry?

Hello investors! Today, we’re taking a look at a heavyweight in the life sciences sector: Veeva Systems (VEEV). If you’re not familiar with them, think of them as a bit like the Salesforce of the healthcare industry. They sell SaaS (subscription-based) software to help pharmaceutical and biotech giants manage their clinical trials, regulatory compliance and sales.

It might not sound the most exciting on paper, but from a business perspective, it’s a real powerhouse. Is now the time to rob a bank to buy some? Let’s take a look straight away.

📊 The Comprehensive Check-up (Rating: /5)

1. Turnover: ⭐⭐⭐⭐⭐

Veeva is all about steady yet rock-solid growth. Revenue has risen from $1.46 billion in 2021 to nearly $3.2 billion in 2026 (fiscal data). It’s a steady, uninterrupted rise. The subscription model is a cash cow: once a pharmaceutical company uses Veeva for its clinical data, it never leaves. That’s what you call a rock-solid ‘moat’ (economic moat).

2. Net profit: ⭐⭐⭐⭐

Net profit follows the same trend. It has risen from $380 million in 2021 to $909 million in 2026. The net margin is impressive (around 28%). They’re not just blowing hot air; they’re printing money. One slight downside: R&D and marketing expenditure remains high to maintain their leadership position, but that’s the price you pay in the tech sector.

3. Debt (Financial stability): ⭐⭐⭐⭐⭐

That’s where it gets outrageous. Take a look at the balance sheet: Total debt = 0. Nada. Peanuts. Yet they’re sitting on a mountain of cash and short-term investments worth over $6.5 billion. Veeva could buy out half its competitors with its pocket money. It’s the lowest-risk profile you’ll find.

4. Return on Equity (ROE): ⭐⭐⭐⭐

With a ROE of around 12–15% (expected to fall slightly to 14.5% by 2031 as equity capital grows significantly), Veeva makes excellent use of its shareholders’ money. Even if the ROE falls slightly because they are accumulating too much cash, operational efficiency remains top-notch.

5. Market performance: ⭐⭐⭐

The share price currently stands at $167.82. That’s solid, but the stock has seen better days (it has previously hit over $300). The market has become a little more demanding when it comes to ‘cloud’ valuations. The current P/E ratio (around 30x) shows that the share is no longer a ‘bargain’, but it is no longer in the stratosphere of the bubble either.

🏆 Overall rating: 4.4/5

Conclusion: Quality: Veeva is a classic “compounder”. It’s a rock-solid company, a leader in its niche, with a financial track record to die for. It’s the sort of share you buy so you can sleep soundly.

🟔 The Future: Where are we heading?

The forecasts are quite ambitious. According to analysts:

  • EPS (Earnings per Share): A sharp rise is expected. From $5.44 in 2026, the target is $8.82 in 2027 and up to nearly $15 in 2031!
  • Revenue: It is expected to exceed the $5 billion mark by 2030.

💾 Share price estimate:

  • 2026 target: With an EPS of $5.44 and a reasonable multiple, the share price is expected to stabilise or rise towards $190–$210.
  • 2027 target: If EPS forecasts of $8 or more are confirmed, we could see a return to the $250–$280 range. The market is waiting to see whether EBITDA growth (expected to rise from $1.6 billion in 2027 to $2.8 billion in 2031) materialises.

⚔ Strengths vs Risks: The Battle

Strengths (Why we love it):

  • De facto monopoly: It’s difficult for a client to leave Veeva once all their healthcare data is on the platform.
  • Defensive sector: Even in an economic crisis, pharmaceutical companies continue to seek new drugs.
  • Insane cash flow: They generate massive operating cash flow ($1.4 billion in 2026).

Risks (Why we’re keeping an eye on them):

  • Market saturation: They already have the biggest clients. Growth must now come from smaller laboratories or new services.
  • Competition: Salesforce is trying to encroach on their territory with ‘Life Sciences Cloud’.
  • Regulation: A major change in the way the FDA handles data could force Veeva to rewrite everything.

In short, Veeva Systems is a bit like the stock market’s ‘ideal son-in-law’.

It is a company that ticks almost every box: predictable growth, massive margins, and, above all, a complete lack of debt, which makes it virtually indestructible in the face of economic turmoil. It does not merely dominate its market; it has made itself indispensable by becoming the digital backbone of the pharmaceutical industry.

If we look at the bare figures:

  • Financial rating: Exceptional (4.4/5).
  • Potential: An expected acceleration in earnings from 2027 onwards could boost the share price.
  • Risk: Low, mainly due to valuation and competition from giants such as Salesforce.

Final thoughts:

It’s the ‘low-maintenance’ investment that might not yield a 100% return in three months, but which has everything it takes to turn your savings into a real little fortune in the long run.
So, shall we add Veeva to your top 10? 😉

  • Signal : Buy
  • Budget/Investment : Medium/High
  • Reinforcement required : Yes, under $100
  • Exposure : Medium/Low
  • Horizon : 2 to 3 years
  • Potential profitability : +51% to +70%
  • Ref. ISIN code : US9224751084
  • Article updated on 13/08/2026: We bought them in April and decided to sell all the shares, resulting in a return of 45% over four months 😎